olivLaw · European equity research
bioMérieux SA BIM.PA
France · Euronext Paris · ISIN FR0013280286 · Vertical: Listed companies from France
bioMérieux is a French group that develops, manufactures and sells in vitro diagnostic solutions for infections and sepsis, combining instruments, reagents and software. Its intellectual property portfolio is broad, and the company invests in partnerships with hospitals and research institutes on topics such as antibiotic resistance and artificial intelligence applied to diagnostics.
At the close of 05 Nov 2026, bioMérieux SA (BIM.PA) stock was 94.75 EUR (−2.97% on the day), with beta 0.29, 52-week range 66.60–114.80 EUR.
Data as of · AI analysis dated · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 71.5
- overbought (≥ 70)
- Bollinger (20, 2)
- 81.83 – 96.04
- in the upper half of the band · %B 0.91 · band width 16.0%
- SMA 50 / 200
- 80.68 / 80.50
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 4.01 / 3.61
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +18.3% | +0.4% | +17.9 pp | — |
| 3 months | +30.7% | −3.3% | +34.0 pp | — |
| 6 months | +32.4% | +4.0% | +28.5 pp | — |
| Year to date | −14.1% | +8.1% | −22.2 pp | — |
| 1 year | −12.6% | +10.7% | −23.3 pp | −6.8% |
| 3 years | +2.2% | +50.1% | −47.9 pp | −15.9% |
| 5 years | −9.4% | +43.6% | −53.0 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
EPS unavailable in the issuer's structured filings (e.g. a partnership reports per unit, not per share).
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 3.7 bn | 4.0 bn | 4.1 bn |
| Revenue YoY | unavailable | +8.3% | +2.3% |
| Net income | 357.6 m | 432.2 m | 397.5 m |
| Net income YoY | unavailable | +20.9% | −8.0% |
| Diluted EPS | unavailable | unavailable | unavailable |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | 9.7% | 10.9% | 9.8% |
| Free cash flow | unavailable | unavailable | unavailable |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 569.8 m EUR
- Financial debt
- unavailable EUR
- Net debt
- unavailable EUR
- Equity
- 4.1 bn EUR
- Total assets
- 5.6 bn EUR
- Debt / equity
- unavailable
- Current ratio
- unavailable
- ROE
- 9.6%
- ROA
- 7.0%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (EUR)
Margins
Income statement · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 3.7 bn | 4.0 bn | 4.1 bn | esef· 18 Mar 2026verified |
| Cost of revenue | 1.6 bn | 1.8 bn | 1.8 bn | esef· 18 Mar 2026verified |
| Gross profit | 2.1 bn | 2.2 bn | 2.3 bn | esef· 18 Mar 2026verified |
| Research & development | 460.1 m | 491.5 m | 507.4 m | esef· 18 Mar 2026verified |
| Operating income | 439.0 m | 588.8 m | 521.3 m | esef· 18 Mar 2026verified |
| Income tax | 114.5 m | 154.3 m | 128.8 m | esef· 18 Mar 2026verified |
| Net income | 357.6 m | 432.2 m | 397.5 m | esef· 18 Mar 2026verified |
Balance sheet · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 352.4 m | 449.8 m | 569.8 m | esef· 18 Mar 2026verified |
| Inventories | — | 1.0 bn | 959.7 m | esef· 18 Mar 2026verified |
| Property, plant & equipment, net | 1.4 bn | 1.5 bn | 1.5 bn | esef· 18 Mar 2026verified |
| Goodwill | 698.8 m | 730.4 m | 727.8 m | esef· 18 Mar 2026verified |
| Intangibles (excl. goodwill) | 528.6 m | 492.0 m | 401.5 m | esef· 18 Mar 2026verified |
| Total assets | 5.3 bn | 5.8 bn | 5.6 bn | esef· 18 Mar 2026verified |
| Equity | 3.8 bn | 4.2 bn | 4.1 bn | esef· 18 Mar 2026verified |
Cash flow · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | 445.4 m | 667.3 m | 788.4 m | esef· 18 Mar 2026verified |
| Investing cash flow | -488.8 m | -359.8 m | -461.7 m | esef· 18 Mar 2026verified |
| Financing cash flow | -122.3 m | -212.6 m | -155.4 m | esef· 18 Mar 2026verified |
| Share repurchases | -12.7 m | 37.6 m | 18.2 m | esef· 18 Mar 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 1 of at least 6
- score weight coverage: 6.2% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Key indicators
Coverage and freshness
Score by group
6% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · input data missing
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 1 of at least 6; score weight coverage: 6.2% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 9.8% | 92 (vs peers) | 100% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | unavailable | unavailable | — |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partialunavailable · 0/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial92/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
BIOMERIEUX SA (BIM.PA). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 4.1 bn EUR in 2025; YoY growth 2.3%; net margin 9.8%; ROE 9.6%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 1 of at least 6; score weight coverage: 6.2% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 9.8%
What contradicts it
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, Current ratio, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from France · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AI.PAL'air Liquide Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | 109.3 bn | 33.2 | 12.9% | 12.2% | −2.0% | +26% / +32% |
| BN.PADanone | 44.1 bn | 21.9 | 11.9% | 7.4% | −0.9% | −11% / +16% |
| AC.PAAccor | 13.8 bn | 30.7 | 9.6% | 8.0% | +0.6% | +6% / +56% |
| ADP.PAAeroports De Paris | 11.7 bn | 34.1 | 7.8% | 5.6% | +12.1% | −7% / +4% |
| AKE.PAArkema | 7.1 bn | 115.4 | 0.9% | 0.7% | −5.0% | +12% / −37% |
| ALO.PAAlstom | 5.8 bn | 18.3 | 3.1% | 1.7% | +3.7% | −51% / −4% |
| AF.PAAir France - Klm | 4.3 bn | 13.6 | — | 1.0% | +4.8% | +20% / +9% |
| ATE.PAAlten | 3.1 bn | 29.5 | 4.8% | 2.6% | −1.1% | +33% / −29% |
| BB.PASociete Bic | 2.7 bn | 31.3 | 5.0% | 4.1% | −4.8% | +32% / +5% |
| ANTIN.PAAntin Infrastructure Partners | 1.4 bn | 13.0 | 21.9% | 36.6% | −8.1% | −24% / −35% |
| 74SW.PA74software | 792.7 m | 20.9 | 8.9% | 8.5% | +44.8% | −13% / +41% |
| AUB.PAAubay | 667.4 m | 17.8 | 13.6% | 6.3% | +11.3% | +3% / +45% |
| ASY.PAAssystem | 507.1 m | 69.9 | 2.5% | 1.1% | +7.4% | −19% / −18% |
| ATO.PAAtos Se | 483.0 m | — | -23,400.0% | -17.5% | −16.5% | −45% / −94% |
| ARAMI.PAAramis Group | 298.8 m | 15.0 | 10.0% | 0.8% | +6.3% | −33% / −16% |
| ARVEN.PAArverne Group | 246.1 m | — | -14.0% | -115.3% | +27.0% | +20% / −35% |
| BGO.PACompagnie Chargeurs Invest | 189.4 m | — | -8.6% | -5.7% | −2.9% | unavailable / unavailable |
| ALCIS.PACatering International & Services | 145.0 m | 28.4 | 9.3% | 1.9% | +5.8% | +39% / +107% |
| ALCGM.PACegedim | 144.6 m | — | -2.6% | -1.2% | +10.9% | −26% / −49% |
| ATEME.PAAteme | 144.0 m | 151.3 | 2.8% | 1.0% | +2.2% | +82% / +77% |
| ALHEX.PAHexaom | 144.0 m | 6.7 | 9.9% | 2.2% | +13.1% | −32% / +7% |
| ALBON.PACompagnie Lebon | 111.7 m | 16.5 | 4.2% | 8.8% | −17.9% | +6% / +8% |
| ALHYF.PALhyfe | 75.8 m | — | -33.4% | -570.5% | +287.2% | unavailable / unavailable |
| ALFER.PASergeferrari Group | 61.5 m | 11.5 | 5.1% | 1.5% | +7.4% | −33% / −27% |
| ABEO.PAAbeo | 60.8 m | 7.3 | 6.9% | 3.0% | +12.6% | −13% / −54% |
1- and 3-year price returns: for BIM.PA from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
bioMérieux is a French group that develops, manufactures and sells in vitro diagnostic solutions for infections and sepsis, combining instruments, reagents and software. Its intellectual property portfolio is broad, and the company invests in partnerships with hospitals and research institutes on topics such as antibiotic resistance and artificial intelligence applied to diagnostics 1.
SWOT
Strengths
- Extensive portfolio of patents and trademarks, protected in the main markets, which supports technological differentiation 1.
- Production model specialised by product line, with scale economies and proximity to research teams 1.
- Solid network of academic and industrial partnerships in areas such as artificial intelligence and antibiotic resistance 1.
Weaknesses
Opportunities
- Validation of artificial intelligence models could extend the usefulness of diagnostics in predicting patient outcomes 1.
- Demand linked to severe infections and sepsis, supported by dedicated research projects, could grow 1.
- Expanding presence in China, where production and research are developing, could open new segments 1.
Risks
- Dependence on patent licencesmedium
Sales of certain products depend on licences granted by third parties, and losing them could affect revenue, although management considers the risk controlled 1.
- Patent expirymedium
High medical value tests may be more sensitive to patent expiry, which could attract generic competitors 1.
- Protection of intellectual propertylow
Active defence of patents and trademarks worldwide involves litigation and costs, and infringements could affect competitive position 1.
- Concentration of productionmedium
Organising production by product line and across a limited number of sites could expose the group to local supply disruptions 1.
- Cold chain and product shelf lifelow
Reagents and culture media have short shelf lives, and a logistics error could affect product availability for customers 1.
Investment thesis
What would need to be true (bull case)
- The large portfolio of patents and trademarks, combined with specialised production, could support the group's differentiation in in vitro diagnostics 1.
- Partnerships with research institutes and university hospitals could bring new applications, particularly in artificial intelligence and antibiotic resistance 1.
- Entry barriers linked to the installed base of instruments and know-how could protect the group's position over the long term 1.
What would break the thesis
- Patent expiry on high medical value tests could open the market to competitors and could reduce margins 1.
- Dependence on external licences could make sales of some products vulnerable to contractual changes 1.
- A distributed production and logistics structure could generate additional costs if it is not optimised 1.
What to watch
- Trend in revenue and margins on high medical value tests as patent expiry approaches2027
- Progress in validating artificial intelligence models from research partnerships2027
- New licence agreements and any changes to existing onesnext 10-K
- Development of activity in China, including local equipment production2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
According to the annual report for the year ended 31 December 2025, bioMérieux protects its products and processes through patents, copyrights and trademarks, and at the end of 2025 it held 466 patent families and 297 trademark families protected in most countries of the world 1. The group organised production on the principle of 'one product range, one site', with 19 production sites at the end of 2025 1. Distribution relies on global and regional storage and shipping platforms, and logistics manages the cold chain and product traceability 1.
Segments
Research and innovation partnerships
bioMérieux collaborates with academic and private institutions, including the MILA institute in Québec for artificial intelligence models and the Institut Pasteur for innovation in infectious diseases, as well as European and French consortia focused on rapid diagnostics and antibiotic resistance 1. Collaborations with university hospitals in the United States targeted sequencing and detection of antimicrobial resistance 1.
Production and logistics
Production is concentrated by product line, with exceptions for culture media, made close to customers because of their short shelf life, and for blood culture bottles, made both in the United States and in China 1. A secure site in Salt Lake City has its own staff, programmes and equipment for military customers in the United States 1.
Market context
The annual report describes the in vitro diagnostics market as less exposed to generic entry than the pharmaceutical industry, because manufacturing know-how, the installed base of instruments and the number of menu parameters developed during the protection period make access harder for new players 1. High medical value tests may, however, be more sensitive to the expiry of the patents protecting them 1.
The company mentions licences of patents on which it depends to sell certain products, and the loss of these could affect revenue, although management considers the risk controlled and not major 1. Protection of the 'bioMérieux' name and trademarks remains central to its commercial strategy in international markets 1.
Trends
- Artificial intelligence in diagnosticstailwind
Partnerships with the MILA institute and the AIRISE project on predicting the severity of respiratory infections point to combining clinical and biological data through artificial intelligence 1. If these models are validated and adopted, they could extend the value of the group's diagnostic solutions.
- Fight against antibiotic resistancetailwind
Projects such as the ARPEGE consortium and THERAPHAGE, which pursue multidisciplinary solutions and the selection of therapeutic phages, indicate growing demand for diagnostics in the context of antibiotic resistance 1.
- Patent expiry on high-value testsheadwind
High medical value tests are, according to the report, more sensitive to patent expiry than complex instruments and menus, which could pressure margins on certain products 1.
- Dependence on external licencesmixed
Certain products depend on patent licences granted by third parties, and changes in these agreements could influence sales, although the company considers them manageable 1.
Competitive position
The annual report indicates that barriers to entry in in vitro diagnostics are high, owing to the installed base of instruments and manufacturing know-how, which limits access for new players 1. Competition nonetheless remains present in high medical value test segments, where patent expiry could open the market 1.
The group's differentiation rests on the combination of instruments, reagents and software, its network of academic partnerships and its portfolio of patents and trademarks 1. Direct competitors are not named in the source analysed, so comparisons with other players should be treated with caution 1.
- Generic in vitro diagnostics players
The report mentions potential new entrants, without naming them, who could enter the market after patents on high medical value tests expire 1.
- Laboratory instrument manufacturers
The source does not identify competitors by name; the diagnostic instruments market remains contested, and the installed base is an advantage to preserve 1.
- Patent licence providers
Third parties granting exclusive licences can influence the product range, and the loss of these licences could affect sales 1.
- Partner institutes and hospitals
Academic partners are at the same time collaborators and potential competitors, through the development of their own research solutions 1.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202518 Mar 2026
- Annual report 202415 Apr 2025
Sources
- [1] Annual report, fiscal year ended 2025-12-31 (ESEF) · SEC / bioMérieux SA · 31 Dec 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.